相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
Mark B. Leick et al.
CANCER CELL (2022)
CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations
Ling Tang et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2022)
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
Xuanqi Cao et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)
Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AML
Gabriele Greve et al.
CANCER RESEARCH (2021)
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
Yao Wang et al.
NATURE COMMUNICATIONS (2021)
Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Kah Keng Wong et al.
FRONTIERS IN ONCOLOGY (2021)
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl et al.
BLOOD ADVANCES (2021)
Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
Camilla M. Grunewald et al.
FRONTIERS IN IMMUNOLOGY (2021)
Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation
Yimei Que et al.
FRONTIERS IN IMMUNOLOGY (2021)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Treatment of Relapsed Acute Myeloid Leukemia
Felicitas Thol et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells
Liangshun You et al.
FRONTIERS IN IMMUNOLOGY (2020)
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D. DiNardo et al.
LANCET HAEMATOLOGY (2020)
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Chimeric antigen receptor T cell persistence and memory cell formation
Alexander D. McLellan et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies
Florence Borot et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Clinical lessons learned from the first leg of the CAR T cell journey
Robbie G. Majzner et al.
NATURE MEDICINE (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Ying Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Precision therapy for acute myeloid leukemia
Xue Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
Silvia Arcangeli et al.
MOLECULAR THERAPY (2017)
Effector CD8 T cells dedifferentiate into long-lived memory cells
Ben Youngblood et al.
NATURE (2017)
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Hazem E. Ghoneim et al.
CELL (2017)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+ T-cell fate decisions following activation
Brian H. Ladle et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Treatment with 5-Aza-2′-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing
Agnes S. Klar et al.
PLOS ONE (2015)
5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
Thomas Stuebig et al.
MEDIATORS OF INFLAMMATION (2014)
DNA methylation by DNA methyltransferase 1 is critical for effector CD8 T cell expansion
Craig Chappell et al.
JOURNAL OF IMMUNOLOGY (2006)
5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia
K Schmelz et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
JPJ Issa et al.
BLOOD (2004)
CD44v6: a target for antibody-based cancer therapy
KH Heider et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival
PP Lee et al.
IMMUNITY (2001)
分享论文
